Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 6 papers. Top paper: “Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study”.
Mehmet A. N. Şendur, Delvys Rodríguez‐Abreu, Keunchil Park, Dae Ho Lee, Irfan Çiçin +15 more
Junwen Yuan, Daobin Wang, Ruisi Wu, Jidong Liu, Xiyao Cheng +3 more
Bo Shao, Gen-lin Wang, Ting-ting Dai, Lu Xu, Jing-yan Huang +1 more
Nathan Kauffman, Lu Xu, Satyendra Kumar Singh, Chelsea Nayback, Jinda Fan +6 more
Yi Xing, Michael Ngatio, Paulina K. Bies, Lu Xu, Liuxi Xing +5 more
Satyendra Kumar Singh, Chelsea Nayback, Abdullah Metebi, Dalen Agnew, Tim Buss +3 more